A Bangladeshi pharma company will soon release a generic version of an expensive drug for cystic fibrosis that will allow hundreds of patients worldwide to access treatment.
The vaccine appears to prime the immune system in a powerful, nonspecific way, enhancing cancer treatment outcomes. If confirmed, the discovery could lead to a universal cancer vaccine and transform oncology care.
Results from this phase showed 88% of mice rejected pancreatic tumors, 75% rejected breast tumors, and 69% rejected melanoma. All tumor-free mice also resisted further cancer spread.